Advances in Immunotherapy for Tuberculosis Treatment

被引：44

作者：

Churchyard, Gavin J. ^{[1
,2
,3
]}

Kaplan, Gilla ^{[4
]}

Fallows, Dorothy ^{[4
]}

Wallis, Robert S. ^{[5
]}

Onyebujoh, Philip ^{[6
]}

Rook, Graham A. ^{[7
]}

机构：

[1] Aurum Inst Hlth Res, ZA-2041 Johannesburg, South Africa

[2] Univ KwaZulu Natal, Nelson R Mandela Sch Med, ZA-4041 Durban, South Africa

[3] Univ Cape Town, Fac Hlth Sci, ZA-7935 Cape Town, South Africa

[4] Univ Med & Dent New Jersey, Publ Hlth Res Inst, Newark, NJ 07103 USA

[5] Pfizer Global Res & Dev, New London, CT 06320 USA

[6] WHO, Trop Dis Res, CH-1211 Geneva 27, Switzerland

[7] Royal Free & Univ Coll Med Sch, Ctr Infect Dis & Int Hlth, Windeyer Inst Med Sci, London W1P 7PP, England

来源：

CLINICS IN CHEST MEDICINE | 2009年 / 30卷 / 04期

关键词：

Tuberculosis; Immunotherapeutics; Antituberculous; Chemotherapy; Pulmonary infection; Immunopathology; TB treatment; NECROSIS-FACTOR-ALPHA; KILLED MYCOBACTERIUM-VACCAE; MULTIDRUG-RESISTANT TUBERCULOSIS; ADJUNCTIVE THALIDOMIDE THERAPY; PULMONARY TUBERCULOSIS; IMMUNE-RESPONSE; IFN-GAMMA; T-CELLS; ANTITUBERCULOSIS TREATMENT; ANTIINFLAMMATORY ACTIVITY;

D O I：

10.1016/j.ccm.2009.08.009

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Immunotherapies have the potential to improve the outcome in all patients with tuberculosis (TB) including those with multidrug-resistant (MDR)-TB and extensively drug-resistant (XDR)-TB. Immunotherapy for TB may shorten duration of treatment and reduce pathology in individuals cured by chemotherapy, potentially preventing recurrence. Currently none of the available candidate agents have proof of efficacy for use in MDR-TB or XDR-TB. Further development and evaluation of existing immunotherapeutic agents is required to identify an effective agent that can be used adjunctively with chemotherapy to improve treatment outcomes for drug-susceptible TB, MDR-TB, and XDR-TB. With a range of potential immunotherapeutics, some of which have been produced to good manufacturing practice (GMP) standards and are registered for other indications in humans, the immunotherapy option should no longer be ignored.

引用

页码：769 / +

页数：15

共 101 条

[71] Tuberculosis Due to High-Dose Challenge in Partially Immune Individuals: A Problem for Vaccination? [J].

Rook, Graham A. W. ;

Hernandez-Pando, Rogelio ;

Zumla, Alimuddin .

JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (05) :613-618

[72] Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice [J].

Roy, E ;

Stavropoulos, E ;

Brennan, J ;

Coade, S ;

Grigorieva, E ;

Walker, B ;

Dagg, B ;

Tascon, RE ;

Lowrie, DB ;

Colston, MJ ;

Jolles, S .

INFECTION AND IMMUNITY, 2005, 73 (09) :6101-6109

[73]

Roy E, 2008, TUBERCULOSIS, V88, P197, DOI [10.1016/j.tube.2007.11.005, 10.1016/S1472-9792(08)70011-8]

[74] Current strategies in TB immunotherapy [J].

Roy, Eleanor ;

Lowrie, Douglas B. ;

Jolles, Stephen R. .

CURRENT MOLECULAR MEDICINE, 2007, 7 (04) :373-386

[75] Improved protection against disseminated tuberculosis by Mycobacterium bovis bacillus Calmette-Guerin secreting murine GM-CSF is associated with expansion and activation of APCs [J].

Ryan, Anthony A. ;

Wozniak, Teresa M. ;

Shklovskaya, Elena ;

O'Donnell, Michael A. ;

Fazekas de St Groth, Barbara ;

Britton, Warwick J. ;

Triccas, James A. .

JOURNAL OF IMMUNOLOGY, 2007, 179 (12) :8418-8424

[76] Adjunctive thalidomide therapy for childhood tuberculous meningitis: Results of a randomized study [J].

Schoeman, JF ;

Springer, P ;

van Rensburg, AJ ;

Swanevelder, S ;

Hanekom, WA ;

Haslett, PAJ ;

Kaplan, G .

JOURNAL OF CHILD NEUROLOGY, 2004, 19 (04) :250-257

[77] Adjunctive thalidomide therapy of childhood tuberculous meningitis: Possible anti-inflammatory role [J].

Schoeman, JF ;

Springer, P ;

Ravenscroft, A ;

Donald, PR ;

Bekker, LG ;

van Rensburg, AJ ;

Hanekom, WA ;

Haslett, PAJ ;

Kaplan, G .

JOURNAL OF CHILD NEUROLOGY, 2000, 15 (08) :497-503

[78] Immunotherapy with plasmid DNA encoding mycobacterial hsp65 in association with chemotherapy is a more rapid and efficient form of treatment for tuberculosis in mice [J].

Silva, CL ;

Bonato, VLD ;

Coelho-Castelo, AAM ;

De Souza, AO ;

Santos, SA ;

Lima, KM ;

Faccioli, LH ;

Rodrigues, JM .

GENE THERAPY, 2005, 12 (03) :281-287

[79]

Simbirtsev Andrey, 2003, Russ J Immunol, V8, P11

[80] Immunization with heat-killed Mycobacterium vaccae stimulates CD8(+) cytotoxic T cells specific for macrophages infected with Mycobacterium tuberculosis [J].

Skinner, MA ;

Yuan, S ;

Prestidge, R ;

Chuk, D ;

Watson, JD ;

Tan, PLJ .

INFECTION AND IMMUNITY, 1997, 65 (11) :4525-4530

← 2 3 4 5 6 7 8 9 10 11 →